Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab
Related Posts
Hanif I, Assassi S, Mayes MD, McMahan ZH, Zhang M, Charles J, VanBuren JM, Alvey JS, Ghaffari K, Bernstein EJ, Castelino FV, Chung L, Evnin[...]
Fung CH, Mak S, Ash G, Der-McLeod E, Ereso J, Naeem S, Liu J, Ghadimi S, Te TT, Chan V, Hurtado J, Wong S, Zeidler[...]
Kawai K, Muhere CF, Lemos EV, Francis JM. Viral Infections and Risk of Cardiovascular Disease: Systematic Review and Meta-Analysis. J Am Heart Assoc. 2025 Oct[...]
